Skip to main content
AS

Asceneuron

Lausanne, Switzerland
Last funding
$100.0M
Series CJul 2024

Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease.

About Asceneuron

How much funding has Asceneuron raised?

Asceneuron has raised $100.0M in total funding. The most recent round was Series C. The last funding was announced in July 2024.

Who are Asceneuron's investors?

Asceneuron's investors include Novo Holdings, OrbiMed, Sofinnova Partners, Kurma Partners, SR One.

Where is Asceneuron headquartered?

Asceneuron is headquartered in Lausanne, Switzerland.

What does Asceneuron do?

Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease.

What stage is Asceneuron at?

Asceneuron is at the Series C stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Asceneuron — Funding & Investors." VCBacked, July 16, 2024, https://www.vcbacked.co/company/asceneuron. Accessed November 13, 2026.
APA
VCBacked. (2024). Asceneuron — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/asceneuron
Wikipedia (cite web)
{{cite web |title=Asceneuron — Funding & Investors |url=https://www.vcbacked.co/company/asceneuron |website=VCBacked |access-date=November 13, 2026}}

Profile data sourced and verified per the VCbacked methodology · Last funding round dated

Work at Asceneuron? Request a listing update

Founder contacts
m***@asceneuron.com
linkedin.com/in/●●●●●●
Emails, phones & LinkedIn · 41,000+ verified contacts
Get instant access →